Inovio Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M), while Wells Fargo & Co trades at $87.71 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 3369.3× Inovio Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WFC | |
|---|---|---|
Market Cap | $78.55M | $264.66B |
Sector | Health | Financials |
52-Week High | $2.87 | $96.40 |
52-Week Low | $0.66 | $73.42 |
Enterprise Value | $49.56M | — |
Dividend Yield | — | 2.29% |
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Wells Fargo (WFC) trades at $87.55, up 0.34% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 12.72, net income margin of 25.97%, and ROE of 13.13%. Recent earnings beat expectations in Q2 2026, and the company is expanding digital services like tokenized deposits. Analyst consensus is mixed but leans positive, with a price target of $97.64.
The outlook for WFC is favorable, driven by earnings growth and strategic innovations, though risks include volatile cash flows and economic sensitivity. Upside potential exists if the company meets future earnings and maintains profitability, but investors should monitor execution and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →